Erez Aminov - 31 Dec 2025 Form 5 Insider Report for MIRA PHARMACEUTICALS, INC. (MIRA)

Reporting relationship: CEO and Chairman, Director
Issuer ticker: MIRA
Reported as of: 31 Dec 2025
Net transaction value: -$522,945
SEC form: 5
Accepted by SEC: 17 Feb 2026, 20:30:02 UTC
Prior SEC filing: 03 Oct 2025
Next SEC filing: 01 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Erez Aminov

Key filing fact

Erez Aminov filed Form 5 for MIRA PHARMACEUTICALS, INC. (MIRA) on 17 Feb 2026.

Key facts

This page summarizes Erez Aminov's Form 5 filing for MIRA PHARMACEUTICALS, INC. (MIRA).
8 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 17 Feb 2026, 20:30.

Change

Previous filing in this sequence was filed on 03 Oct 2025.
Current net transaction value: -$522,945.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 5 disclosures.

View source filing

Reporting Owners (1)

CIK 0001986112 Primary reporting owner

Aminov Erez

Relationship: CEO and Chairman, Director
Address: C/O MIRA PHARMACEUTICALS, INC., 1200 BRICKELL AVE. SUITE 1950 #1183, MIAMI
Signature: /s/ Erez Aminov
Signature date: 17 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MIRA transaction

Common Stock

Award

Transaction value: $90,625
Shares: +62,500
Change %: +1.8%
Price: $1.45
Shares after: 3,530,166
Date: 26 Mar 2025
Ownership: Direct
Footnotes: F1, F2

MIRA transaction

Common Stock

Award

Transaction value: $90,625
Shares: +62,500
Change %: +1.8%
Price: $1.45
Shares after: 3,592,666
Date: 26 Mar 2025
Ownership: Direct
Footnotes: F1, F2

MIRA transaction

Common Stock

Options Exercise

Transaction value: $272,130
Shares: +234,595
Change %: +6.5%
Price: $1.16
Shares after: 3,827,259
Date: 16 Oct 2025
Ownership: Direct
Footnotes: F1, F3

MIRA transaction

Common Stock

Options Exercise

Transaction value: $318,360
Shares: +379,000
Change %: +9.9%
Price: $0.8400
Shares after: 4,206,259
Date: 16 Oct 2025
Ownership: Direct
Footnotes: F1, F4

MIRA transaction

Common Stock

Sale

Transaction value: $1,294,685
Shares: -613,595
Change %: -15%
Price: $2.11
Shares after: 3,592,666
Date: 16 Oct 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MIRA transaction Derivative

Stock Options (right to buy)

Options Exercise

Transaction value: $0
Shares: +234,595
Change %
Price: $0.000000
Shares after: 234,595
Date: 16 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: $234,595
Exercise price: $1.16
Footnotes: F3

MIRA transaction Derivative

Stock Options (right to buy)

Options Exercise

Transaction value: $0
Shares: +379,000
Change %
Price: $0.000000
Shares after: 379,000
Date: 16 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 379,000
Exercise price: $0.8400
Footnotes: F4

MIRA transaction Derivative

Stock Options (right to buy)

Award

Transaction value: $0
Shares: +3,155,170
Change %
Price: $0.000000
Shares after: 3,155,170
Date: 17 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,155,170
Exercise price: $1.45
Footnotes: F1, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Represents the grant of Issuer's common stock, par value $0.0001 ("Common Stock") that should have been reported on Form 4.

Footnote F2

Represents grants of RSUs with underlying shares of Common Stock under the Issuer's 2024 Omnibus Equity Incentive Plan (the "Plan"), for awards granted in accordance with the Issuer's CEO's Long-Term Incentive Plan. The RSUs hereunder vested upon issuance.

Footnote F3

Represents exercise of 234,595 stock options to purchase Common Stock under the Plan that were issued to the Reporting Person on March 26, 2024, with 50% of such options vesting on the six-month anniversary date of the grant, and the remaining half vesting on the one-year anniversary date of the grant, pursuant to a grant under the Plan at an exercise price of $1.16 each.

Footnote F4

Represents exercise of 379,000 stock options to purchase Common Stock under the Plan that were issued to the Reporting Person on May 28, 2024 that were vested in full and became exercisable on the same date, pursuant to a grant under the Plan at an exercise price of $0.84 each.

Footnote F5

Represents grants of options with underlying shares of Common Stock under the Plan, for awards granted in accordance with the Issuer's CEO's Long-Term Incentive Plan. The options hereunder vested upon issuance.